Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (11-20 of 252) with videos related to

Pageof 26
Sort By:
Alimentary Pharmacology & Therapeutics|April 1, 2022
Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Authors' replyXavier Roblin, Stephane Paul
The American Journal of Gastroenterology|December 1, 2015
Response to SteenholdtS Paul, Xavier Roblin
Therapeutic Advances in Gastroenterology|February 1, 2018
Inflammatory bowel disease: towards a personalized medicineMathurin Flamant, Xavier Roblin
The New England Journal of Medicine|December 28, 2005
Primary biliary cirrhosisXavier Roblin, Bruno Bonaz
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?Xavier Roblin, Stephane Nancey
Therapeutic Advances in Gastroenterology|March 14, 2017
Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?Nicolas Williet, Xavier Roblin
Alimentary Pharmacology & Therapeutics|July 18, 2019
Letter: immunogenicity of anti-TNF in elderly IBD patientsStephane Paul, Xavier Roblin
Archives of Internal Medicine|March 26, 2008
Risks of combining immunosuppressive and biological treatments in inflammatory bowel diseaseXavier Roblin, Jean Marc Phelip
The American Journal of Gastroenterology|February 22, 2007
Type 2 diabetes mellitus and colorectal cancer risk: is homocysteine the missing link?Jean Marc Phelip, Xavier Roblin
The American Journal of Gastroenterology|February 26, 2009
Biological plausibility between proton pump inhibitory therapy and hip fracture: hyperhomocysteinemia can be the linkXavier Roblin, Jean Marc Phelip
Pageof 26

Showing results (11-20 of 252) with videos related to

Sort By:
Pageof 26
Alimentary Pharmacology & Therapeutics|April 1, 2022
Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Authors' replyXavier Roblin, Stephane Paul
The American Journal of Gastroenterology|December 1, 2015
Response to SteenholdtS Paul, Xavier Roblin
Therapeutic Advances in Gastroenterology|February 1, 2018
Inflammatory bowel disease: towards a personalized medicineMathurin Flamant, Xavier Roblin
The New England Journal of Medicine|December 28, 2005
Primary biliary cirrhosisXavier Roblin, Bruno Bonaz
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?Xavier Roblin, Stephane Nancey
Therapeutic Advances in Gastroenterology|March 14, 2017
Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?Nicolas Williet, Xavier Roblin
Alimentary Pharmacology & Therapeutics|July 18, 2019
Letter: immunogenicity of anti-TNF in elderly IBD patientsStephane Paul, Xavier Roblin
Archives of Internal Medicine|March 26, 2008
Risks of combining immunosuppressive and biological treatments in inflammatory bowel diseaseXavier Roblin, Jean Marc Phelip
The American Journal of Gastroenterology|February 22, 2007
Type 2 diabetes mellitus and colorectal cancer risk: is homocysteine the missing link?Jean Marc Phelip, Xavier Roblin
The American Journal of Gastroenterology|February 26, 2009
Biological plausibility between proton pump inhibitory therapy and hip fracture: hyperhomocysteinemia can be the linkXavier Roblin, Jean Marc Phelip
Pageof 26